A bit more:
We assume payments to Shire will amount to roughly 15% of the total present value of profits. The value remaining for AVX shareholders, assuming another 100m shares issued to fund the Phase III trials, equates to ~$1.10 a share. This calculation assumes sales begin in 2010 and peak at $A680m in 2012